Technical Analysis for XNCR - Xencor, Inc.

Grade Last Price % Change Price Change
D 44.9 1.61% 0.71
XNCR closed up 1.61 percent on Friday, March 5, 2021, on 1.22 times normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical XNCR trend table...

Date Alert Name Type % Chg
Hammer Candlestick Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Lizard Bullish Bullish Day Trade Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Below Lower BB Weakness 1.61%
Down 3 Days in a Row Weakness 1.61%
Down 4 Days in a Row Weakness 1.61%
Older End-of-Day Signals for XNCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xencor, Inc. Description

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Immunology Immune System Antibodies Autoimmune Diseases Monoclonal Antibodies Autoimmune Disease Antibody Rheumatoid Arthritis Asthma Glycoproteins Lupus Treatment Of Autoimmune Disease Treatment Of Autoimmune Diseases Boehringer Ingelheim Antibody Product Catalent Immunoglobulin E Manufacturing Services Agreement

Is XNCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 55.33
52 Week Low 19.35
Average Volume 211,145
200-Day Moving Average 39.31
50-Day Moving Average 48.17
20-Day Moving Average 49.49
10-Day Moving Average 47.02
Average True Range 2.77
ADX 17.67
+DI 18.71
-DI 20.81
Chandelier Exit (Long, 3 ATRs ) 47.02
Chandelier Exit (Short, 3 ATRs ) 51.03
Upper Bollinger Band 55.34
Lower Bollinger Band 43.63
Percent B (%b) 0.11
BandWidth 23.66
MACD Line -0.92
MACD Signal Line -0.13
MACD Histogram -0.7899
Fundamentals Value
Market Cap 2.58 Billion
Num Shares 57.5 Million
EPS 0.61
Price-to-Earnings (P/E) Ratio 73.97
Price-to-Sales 28.14
Price-to-Book 4.17
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 48.74
Resistance 3 (R3) 48.44 46.86 48.10
Resistance 2 (R2) 46.86 45.88 47.01 47.89
Resistance 1 (R1) 45.88 45.28 45.09 46.18 47.67
Pivot Point 44.30 44.30 43.91 44.45 44.30
Support 1 (S1) 43.32 43.32 42.53 43.62 42.13
Support 2 (S2) 41.74 42.72 41.89 41.91
Support 3 (S3) 40.76 41.74 41.70
Support 4 (S4) 41.06